Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 6716419, 12 pages
https://doi.org/10.1155/2017/6716419
Research Article

Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis

1Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland
2Department of Pathomorphology, Medical University of Lodz, Lodz, Poland
3Department of Nephropathology, Medical University of Lodz, Lodz, Poland
4Department of Immunopathology, Chair of Allergy, Immunology and Dermatology, Medical University of Lodz, Lodz, Poland

Correspondence should be addressed to K. Juczynska; moc.oohay@aksnyzcuj

Received 24 April 2017; Revised 22 August 2017; Accepted 7 September 2017; Published 24 October 2017

Academic Editor: Sandra Helena Penha Oliveira

Copyright © 2017 K. Juczynska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. B. Yancey and C. A. Egan, “Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations,” The Journal of the American Medical Association, vol. 284, no. 3, pp. 350–356, 2000. View at Publisher · View at Google Scholar
  2. S. J. Galli, J. R. Gordon, and B. K. Wershil, “Cytokine production by mast cells and basophils,” Current Opinion in Immunolology, vol. 3, no. 6, pp. 865–872, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Galli, “New concepts about the mast cell,” The New England Journal of Medicine, vol. 328, no. 4, pp. 257–265, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Kasperkiewicz and D. Zillikens, “The pathophysiology of bullous pemphigoid,” Clinical Reviews in Allergy & Immunology, vol. 33, no. 1, pp. 67–77, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. A. LoSchiavo, E. Ruocco, G. Brancaccio, S. Caccavale, V. Ruocco, and R. Wolf, “Bullous pemphigoid: ethiology, pathogenesis, and inducing factors: facts and controversies,” Clinics in Dermatology, vol. 31, no. 4, pp. 391–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kasperkiewicz, D. Zillikiens, and E. Schmidt, “Pemphigoid diseases: pathogenesis, diagnosis, and treatment,” Autoimmunity, vol. 45, no. 1, pp. 55–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Dieterich, E. Laag, L. Bruckner-Tuderman et al., “Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis,” Journal of Investigative Dermatology, vol. 113, no. 1, pp. 133–136, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Sárdy, S. Kárpáti, B. Merkl, M. Paulsson, and N. Smyth, “Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis,” Journal of Experimental Medicine, vol. 195, no. 6, pp. 747–757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. J. N. Ihle, B. A. Witthuhn, F. W. Quelle, K. Yamamoto, and O. Silvennoinen, “Signaling through the hematopoietic cytokine receptors,” Annual Review of Immunology, vol. 13, pp. 369–398, 1995. View at Publisher · View at Google Scholar
  10. M. Cnop, N. Welsh, J. C. Jonas, A. Jӧrns, S. Lenzen, and D. L. Eizirik, “Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes,” Diabetes, vol. 54, Supplement 2, pp. 97–107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Sigurdsson, G. Nordmark, H. H. Gӧring et al., “Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus,” The American Journal of Human Genetics, vol. 76, no. 3, pp. 528–537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. G. Walker, M. J. Ahern, M. Coleman et al., “Characterisation of a dendritic cell subset in synovial tissue which strongly express Jak/STAT transcription factors from patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 8, pp. 992–999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Anderson, D. C. O. Massey, J. C. Barret et al., “Investigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationship,” Gastroenterology, vol. 136, no. 2, pp. 523–529, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. R. Ferguson, D. Y. Han, A. G. Fraser et al., “Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population,” Mutation Research, vol. 690, no. 1-2, pp. 108–115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Bao, H. Zhang, and L. S. Chan, “The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis,” JAKSTAT, vol. 2, no. 3, article e24137, 2013. View at Publisher · View at Google Scholar
  16. A. Hald, R. M. Andrés, M. L. Salskov-Iversen, R. B. Kjellerup, L. Iversen, and C. Johansen, “STAT1 expression and activation is increased in lesional psoriatic skin,” British Journal of Dermatology, vol. 168, no. 2, pp. 302–310, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. R. Vartoukian, W. M. Tilakaratne, N. Seoudi et al., “Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren’s syndrome,” Clinical & Experimental Immunology, vol. 177, no. 3, pp. 618–629, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. A. B. Ackerman, N. Chongchitnant, J. Sanchez et al., Histologic Diagnosis of Inflammatory Skin Disease: An Algorithmic Method Based on Pattern Analysis, Wiliams & Wilkins, Baltimore, MD, USA, 2nd edition, 1997.
  19. L. Tam, L. M. Mc Glynn, P. Traynor, R. Mukherjee, J. M. Bartlett, and J. Edwards, “Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer,” British Journal of Cancer, vol. 97, no. 3, pp. 378–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. K. S. McCarty Jr., E. Szabo, J. L. Flowers et al., “Use of a monoclonal anti-estrogen receptor antibody of the immunohistochemical evaluation of human tumors,” Cancer Research, vol. 46, no. 8, pp. 4244–4248, 1986. View at Google Scholar
  21. H. Nishio, K. Matsui, H. Tsuji, A. Tamura, and K. Suzuki, “Immunolocalisation of the janus kinases (JAK)-signal transducers and activators of transcription (STAT) pathway in human epidermis,” Journal of Anatomy, vol. 198, pp. 581–589, 2001. View at Publisher · View at Google Scholar
  22. J. Schaller, T. Giese, M. Ladusch, and U. F. Haustein, “Interleukin-2 receptor expression and interleukin-2 production in bullous pemphigoid,” Archives of Dermatological Research, vol. 282, no. 4, pp. 223–226, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Schmidt, A. Ambach, B. Bastian, E. B. Brӧcker, and D. Zillikens, “Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects,” Journal of the American Academy of Dermatology, vol. 34, no. 2, pp. 310–312, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Schindler and I. Strehlow, “Cytokines and STAT signaling,” Advances in Pharmacology, vol. 47, pp. 113–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. J. E. Darnell Jr., “STATs and gene regulation,” Science, vol. 277, no. 5332, pp. 1630–1635, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Iwata, K. Komura, M. Kodera et al., “Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid,” Archives of Dermatology, vol. 144, no. 1, pp. 41–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Schmidt, B. Bastian, R. Dummer, H. P. Tony, E. B. Brӧcker, and D. Zillikens, “Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid,” Archives of Dermatological Research, vol. 288, no. 7, pp. 353–357, 1996. View at Publisher · View at Google Scholar
  28. E. Schmidt, A. Mittnacht, H. Schӧmig, R. Dummer, E. B. Brӧcker, and D. Zillikens, “Detection of IL-1α, IL-1β and IL-1 receptor antagonist in blister fluid of bullous pemphigoid,” Journal of Dermatological Science, vol. 11, no. 2, pp. 142–147, 1996. View at Publisher · View at Google Scholar
  29. F. Ameglio, L. D’Auria, C. Bonifati, C. Ferraro, A. Mastroianni, and B. Giacalone, “Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationship with disease intensity,” The British Journal of Dermatology, vol. 138, no. 4, pp. 611–614, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Inaoki and K. Takehara, “Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid,” Journal of Dermatological Science, vol. 16, no. 2, pp. 152–157, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. L. D’Auria, T. Bonifati, P. Cordiali-Fei et al., “Increased serum interleukin-15 levels in bullous skin diseases: correlation with disease intensity,” Archives of Dermatological Research, vol. 291, no. 6, pp. 354–356, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Wakugawa, K. Nakamura, H. Hino et al., “Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemhigoid: correlation with tissue eosinophilia,” The British Journal of Dermatology, vol. 143, no. 1, pp. 112–116, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Frezzolini, G. Cianchini, M. Ruffelli, S. Cadoni, P. Puddu, and O. de Pità, “Interleukin-16 expression and release in bullous pemphigoid,” Clinical and Experimental Immunology, vol. 137, no. 3, pp. 595–600, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Günther, N. Carballido-Perrig, T. Kopp, J. M. Carballido, and C. Pfeiffer, “CCL18 is expressed in patients with bullous pemphigoid and paralells disease course,” The British Journal of Dermatology, vol. 160, no. 4, pp. 747–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. R. J. Ludwig and E. Schmidt, “Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?” Giornale Italiano di Dermatologia e Venereologia, vol. 144, no. 4, pp. 339–349, 2009. View at Google Scholar
  36. A. Zebrowska, M. Wagrowska-Danilewicz, M. Danilewicz et al., “IL-17 expression in dermatitis herpetiformis and bullous pemphigoid,” vol. 2013, Article ID 967987, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Takeda, T. Tanaka, W. Shi et al., “Essential role of Stat6 in IL-4 signalling,” Nature, vol. 380, no. 6575, pp. 627–630, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. W. E. Thierfelder, J. M. Van Deursen, K. Yamamoto et al., “Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells,” Nature, vol. 382, no. 6587, pp. 171–177, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. J. J. O’Shea and R. Plenge, “JAKs and STATs in immunoregulation and immune-mediated disease,” Immunity, vol. 36, no. 4, pp. 542–550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. P. C. Heinrich, I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve, “Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway,” Biochemical Journal, vol. 334, pp. 297–314, 1998. View at Publisher · View at Google Scholar
  41. J. J. O’Shea and P. J. Murray, “Cytokine signaling modules in inflammatory responses,” Immunity, vol. 28, no. 4, pp. 477–487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. McGovern and C. A. Notley, “Production of IL-17: what’s STAT got to do with it?” JAKSTAT, vol. 1, no. 2, pp. 80–82, 2012. View at Publisher · View at Google Scholar
  43. N. M. Gharavi, J. A. Alva, K. P. Mouillesseaux et al., “Role of the JAK/STAT pathway in the regulation of Interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo,” The Journal of Biological Chemistry, vol. 282, no. 43, pp. 31460–31468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews Cancer, vol. 9, no. 11, pp. 798–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. K. Raychaudhuri, C. Abria, and S. P. Raychaudhuri, “Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 76, no. 10, 2017. View at Publisher · View at Google Scholar
  46. J. J. O’Shea, D. M. Schwartz, A. V. Villarino, M. Gadina, I. B. McInnes, and A. Laurence, “The JAK-STAT pathway: impact on human disease and therapeutic intervention,” Annual Review of Medicine, vol. 66, no. 1, pp. 311–328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Wu, T. Yang, X. Liu et al., “IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer,” Tumour Biology, vol. 37, no. 4, pp. 5493–5501, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Damsky and B. A. King, “JAK inhibitors in dermatology: the promise of a new drug class,” Journal of American Academy of Dermatology, vol. 76, no. 4, pp. 736–744, 2017. View at Publisher · View at Google Scholar
  49. S. Miscia, M. Marchisio, A. Grilli et al., “Tumor necrosis factor alpha (TNF-α) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells,” Cell Growth & Differentiation, vol. 13, no. 1, pp. 13–18, 2002. View at Google Scholar
  50. S. Toosi and J. C. Bystryn, “Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid,” Medical Hypotheses, vol. 74, no. 4, pp. 727-728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. V. Dahl, J. R. Falk, R. Carpenter, and A. F. Michael, “Membrane attack complex of complement in dermatitis herpetiformis,” Archives of Dermatology, vol. 121, no. 1, pp. 70–72, 1985. View at Publisher · View at Google Scholar
  52. R. P. Hall 3rdF. Takeuchi, K. M. Benbenisty, and R. D. Streilein, “Cutaneous endothelial cell activation in normal skin of patients with dermatitis herpetiformis associated with increased serum levels of IL-8, sE-selectin and TNF-α,” Journal of Investigative Dermatology, vol. 126, no. 6, pp. 1331–1337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Takeuchi, R. D. Stenlein, and R. P. Hall 3rd, “Increased E-selectin, IL-8 and IL-10 gene expression in human skin after minimal trauma,” Experimental Dermatology, vol. 12, no. 6, pp. 777–783, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Graeber, B. S. Baker, J. J. Garioch, H. Valdimarsson, J. N. Leonard, and L. Fry, “The role of cytokines in the generation of skin lesions in dermatitis herpetiformis,” The British Journal of Dermatology, vol. 129, no. 6, pp. 530–553, 1993. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Zebrowska, M. Wagrowska-Danilewicz, M. Danilewicz et al., “Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis,” Mediators of Inflammation, vol. 2014, Article ID 936545, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Pazdrak, S. Stafford, and R. Alam, “The activation of the Jak-STAT1 signaling pathway by IL-5 in eosinophils,” The Journal of Immunology, vol. 155, no. 1, pp. 397–402, 1995. View at Google Scholar
  57. T. Kaneko, K. Tamai, Y. Matsuzaki et al., “Interferon-γ down-regulates expression of the 230-kDa bullous pemphigoid antigen gene (BPAG1) in epidermal keratinocytes via novel chimeric sequences of ISRE and GAS,” Experimental Dermatology, vol. 15, no. 4, pp. 308–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. L. B. Ivashkiv and L. T. Donlin, “Regulation of type I interferon responses,” Nature Reviews Immunology, vol. 14, no. 1, pp. 36–49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Rosińska-Borkowska, “Choroby pęcherzowe o podłożu autoimmunologicznym,” in Dermatologia pediatryczna, Volumed, Volumed, Wroclaw, Poland, 1999. View at Google Scholar
  60. H. L. Rajala, S. Eldfors, H. Kuudanmaki et al., “Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia,” Blood, vol. 121, pp. 4541–4550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Arnould, C. Philippe, V. Bourdon, M. J. Grgoire, R. Berger, and P. Jonveaux, “The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia,” Human Molecular Genetics, vol. 8, no. 9, pp. 1741–1749, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Asao, C. Okuyama, S. Kumaki et al., “Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex,” Journal of Immunology, vol. 167, no. 1, pp. 1–5, 2001. View at Publisher · View at Google Scholar
  63. K. Ghoresci, A. Laurence, and J. J. O’Shea, “Selectivity and therapeutic inhibition of kinases: to be or not to be?” Nature Immunology, vol. 10, pp. 356–360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. L. D’Auria, M. Pietravalle, A. Mastroianni et al., “IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity,” Archives of Dermatological Research, vol. 290, no. 1-2, pp. 25–27, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. A. I. Oikarinen, T. Reunala, J. J. Zone, U. Kiistala, and J. Uitto, “Proteolitic enzymes in blister fluids from patients with dermatitis herpetiformis,” The British Journal of Dermatology, vol. 114, no. 3, pp. 295–302, 1986. View at Publisher · View at Google Scholar · View at Scopus
  66. M. V. Clarindo, A. T. Possebon, E. M. Soligo, H. Uyeda, R. T. Ruaro, and J. C. Empinotti, “Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment,” Anais Brasileiros de Dermatologia, vol. 89, no. 6, pp. 865–877, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Airola, T. Reunala, S. Salo, and U. K. Saarialho-Kere, “Urokinase plasminogen activator is expressed by basal keratinocytes before interstitial collagenase, stromelysin-1, and laminin-5 in experimentally induced dermatitis herpetiformis,” Journal of Investigative Dermatology, vol. 15, no. 2, pp. 184–189, 1995. View at Publisher · View at Google Scholar
  68. K. Takatsu and H. Nakajima, “IL-5 and eosinophilia,” Current Opinion in Immunology, vol. 20, no. 3, pp. 288–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. L. Krebs and D. J. Hilton, “SOCS proteins: negative regulators of cytokine signaling,” Stem Cells, vol. 19, no. 5, pp. 378–387, 2001. View at Publisher · View at Google Scholar
  70. K. Shuai, “Modulation of STAT signaling by STAT-interacting proteins,” Oncogene, vol. 19, no. 21, pp. 2638–2644, 2000. View at Publisher · View at Google Scholar
  71. A. V. Villarino, Y. Kanno, and J. J. O’Shea, “Mechanisms of Jak/STAT signaling in immunity and disease,” The Journal of Immunology, vol. 194, no. 1, pp. 21–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. J. J. O’Shea, J. Sims, and R. M. Siegel, “Cytokines,” in Rheumatology, M. C. Hochberg, A. J. Silman AJ, J. S. Smolen, M. E. Weinblatt, and M. H. Weisman, Eds., pp. 91–103, Elsevier, Philadelphia, PA, USA, 2011. View at Google Scholar
  73. M. Gadina, “Janus kinases: an ideal target for the treatment of autoimmune diseases,” Journal of Investigative Dermatology Proceedings, vol. 16, pp. S70–S72, 2013. View at Publisher · View at Google Scholar
  74. M. W. Karaman, S. Herrgard, D. K. Treiber et al., “A quantitative analysis of kinase inhibitor selectivity,” Nature Biotechnology, vol. 26, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Hsu and A. W. Armstrong, “JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis,” Journal of Immunology Research, vol. 2014, Article ID 283617, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus